胃癌腹膜转移行肿瘤细胞减灭术联合或不联合腹腔热灌注化疗(CYTO-CHIP研究):倾向性评分分析
基于法国19个中心1989至2014年前瞻性数据库,纳入277例接受完整肿瘤细胞减灭术的胃癌腹膜转移患者,其中180例联合腹腔热灌注化疗、97例单纯手术。经倾向性评分逆概率加权调整后,联合组中位总生存18.8个月优于单纯手术组12.1个月,复发无生存亦改善,且90天死亡率与严重并发症率无显著差异。
要点
- 联合组中位总生存18.8个月 vs 单纯手术组12.1个月,调整后HR 0.60(95%CI 0.42-0.86,P=.005)。
- 联合组3年、5年无复发生存率分别为20.40%、17.05%,单纯手术组为5.87%、3.76%(P=.001)。
- 两组90天死亡率(7.4% vs 10.1%,P=.820)与严重并发症率(53.7% vs 55.3%,P=.496)无显著差异。
核心结论
- 与单纯肿瘤细胞减灭术相比,联合腹腔热灌注化疗改善总生存和无复发生存,且未增加并发症或死亡。
- 在可完成完整肿瘤细胞减灭术时,对严格选择的局限性胃癌腹膜转移患者,可考虑肿瘤细胞减灭术联合腹腔热灌注化疗。
研究设计与样本
- 基于前瞻性数据库,纳入1989至2014年法国19个中心277例胃癌腹膜转移接受完整肿瘤细胞减灭术(无残留结节>2.5 mm)的患者。
- 其中180例接受肿瘤细胞减灭术联合腹腔热灌注化疗,97例接受单纯肿瘤细胞减灭术。
- 采用基于倾向性评分的逆概率加权Cox比例风险回归模型评估腹腔热灌注化疗效应并校正混杂因素。
- 肿瘤负荷采用腹膜癌指数评估。
主要发现
- 逆概率加权调整后两组基线相似,但联合组中位腹膜癌指数仍较高(6 vs 2,P=.003)。
- 联合组与单纯手术组中位总生存分别为18.8个月与12.1个月,调整后HR 0.60(95%CI 0.42-0.86,P=.005)。
- 联合组与单纯手术组3年总生存率分别为26.21%与10.82%,5年总生存率分别为19.87%与6.43%。
- 联合组与单纯手术组3年无复发生存率分别为20.40%与5.87%,5年无复发生存率分别为17.05%与3.76%(P=.001)。
- 联合组与单纯手术组90天死亡率分别为7.4%与10.1%(P=.820),严重并发症率分别为53.7%与55.3%(P=.496),均无显著差异。
临床怎么用
- 作者认为,当可完成完整肿瘤细胞减灭术时,对严格选择的局限性胃癌腹膜转移患者,可考虑肿瘤细胞减灭术联合腹腔热灌注化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to compare outcomes between CRS-HIPEC versus CRS alone (CRSa) among patients with PMs from GC. PATIENTS AND METHODS: From prospective databases, we identified 277 patients with PMs from GC who were treated with complete CRS with curative intent (no residual nodules > 2.5 mm) at 19 French centers from 1989 to 2014. Of these patients, 180 underwent CRS-HIPEC and 97 CRSa. Tumor burden was assessed using the peritoneal cancer index. A Cox proportional hazards regression model with inverse probability of treatment weighting (IPTW) based on propensity score was used to assess the effect of HIPEC and account for confounding factors. RESULTS: After IPTW adjustment, the groups were similar, except that median peritoneal cancer index remained higher in the CRS-HIPEC group (6 v 2; P = .003). CRS-HIPEC improved overall survival (OS) in both crude and IPTW models. Upon IPTW analysis, in CRS-HIPEC and CRSa groups, median OS was 18.8 versus 12.1 months, 3- and 5-year OS rates were 26.21% and 19.87% versus 10.82% and 6.43% (adjusted hazard ratio, 0.60; 95% CI, 0.42 to 0.86; P = .005), and 3- and 5-year recurrence-free survival rates were 20.40% and 17.05% versus 5.87% and 3.76% (P = .001), respectively; the groups did not differ regarding 90-day mortality (7.4% v 10.1%, respectively; P = .820) or major complication rate (53.7% v 55.3%, respectively; P = .496). CONCLUSION: Compared with CRSa, CRS-HIPEC improved OS and recurrence-free survival, without additional morbidity or mortality. When complete CRS is possible, CRS-HIPEC may be considered a valuable therapy for strictly selected patients with limited PMs from GC.
引用
- Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol. 2019. PMID: 31084544. doi:10.1200/JCO.18.01688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。